Anika Therapeutics | Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Abbott USD 3.13B 125M 2025-12
Agenus USD 23.6M 448K 2025-09
Agios Pharmaceuticals USD 41.27M 4.6M 2025-09
Anika Therapeutics USD 12.91M 17.8M 2025-03
Arrowhead Research USD 46.02M 8.84M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 37.53M 4.53M 2025-09
Heron Therapeutics USD 23.34M 4.18M 2024-09
Insmed USD 186.38M 109.94M 2025-09
Integra LifeSciences USD 169.05M 10.84M 2025-09
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.75B 831M 2025-12
Karyopharm Therapeutics USD 27.19M 442K 2024-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
MacroGenics USD 9.9M 600K 2025-09
Merit Medical Systems USD 107.38M 5.72M 2025-09
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Smith & Nephew USD 1.42B 65M 2025-12
Stryker USD 2.14B 150M 2025-12
Surmodics USD 14.58M 2.05M 2024-09
Veracyte USD 51.73M 5.91M 2025-09
Xencor USD 87.78M 72.66M 2025-09
Zimmer Biomet Holdings USD 855.7M 44.3M 2025-12


Anika Therapeutics Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.